Breast Cancer: UK’s New Drug Slows Progression, Italy’s Arrival
- LONDON (AP) — A new medication offering a potential alternative to chemotherapy for some breast cancer patients has been approved for use in the United kingdom.Capivasertib, designed to...
- The drug functions by blocking a specific protein that fuels the uncontrolled multiplication of cancer cells.
- The announcement has been met with enthusiasm from researchers,with the Institute of Cancer Research in london describing it as a potential "turning point" in treatment.
New Breast Cancer Drug Offers Hope, Approved in UK
Table of Contents
- New Breast Cancer Drug Offers Hope, Approved in UK
- New Breast Cancer drug: Capivasertib – your Questions Answered
- What is capivasertib?
- How Does Capivasertib Work?
- Who Can Benefit From Capivasertib?
- Where Has Capivasertib Been Approved?
- What are the benefits of Capivasertib?
- Why is the UK approval significant?
- What is the status of Capivasertib in Italy?
- Experts describe Capivasertib as a “turning point.” Why?
- What Are the Key Differences Between Capivasertib and Chemotherapy?
LONDON (AP) — A new medication offering a potential alternative to chemotherapy for some breast cancer patients has been approved for use in the United kingdom.Capivasertib, designed to slow the progression of the disease, has been given the green light by British health authorities.
Capivasertib Targets Cancer Cell Growth
The drug functions by blocking a specific protein that fuels the uncontrolled multiplication of cancer cells. This mechanism is notably relevant for patients with HR-positive, HER2-negative breast cancer, a common form of the disease.
Scientific Community Hails ‘turning Point’
The announcement has been met with enthusiasm from researchers,with the Institute of Cancer Research in london describing it as a potential “turning point” in treatment. The drug has already received approval at the European level.
Italian Approval and Accessibility
Italy’s drug agency, AIFA, has also authorized Capivasertib. Though, it is indeed not yet covered by the National Health Service in Italy.Procedures are underway to ensure Italian patients can access the therapy.
Potential to Improve Quality of Life
Capivasertib offers a significant advantage, especially for patients with advanced breast cancer who may have limited treatment options and frequently enough experience severe side effects. The pill-based therapy has the potential to improve patients’ quality of life and delay the need for more invasive interventions.
UK Approval a signal for Europe
The approval of Capivasertib in the United Kingdom is considered a crucial step in making the treatment more widely available and sends a strong signal to the broader european medical community.
New Breast Cancer drug: Capivasertib – your Questions Answered
Are you or a loved one affected by breast cancer? There’s a new medication offering a beacon of hope. Let’s explore Capivasertib.
What is capivasertib?
Capivasertib is a new medication approved in the UK for some breast cancer patients. It’s designed to slow the progression of the disease, offering a potential alternative to chemotherapy.
How Does Capivasertib Work?
Capivasertib targets cancer cell growth by blocking a specific protein that fuels the uncontrolled multiplication of cancer cells.
Who Can Benefit From Capivasertib?
This drug is notably relevant for patients with HR-positive, HER2-negative breast cancer, which is a common type of the disease.
Where Has Capivasertib Been Approved?
Has Capivasertib been approved in Europe?
Yes, Capivasertib has been approved at the European level. It’s also been approved for use in the United Kingdom.
Has Capivasertib been approved in Italy?
Yes, Italy’s drug agency (AIFA) has authorized Capivasertib.
What are the benefits of Capivasertib?
Capivasertib offers a critically important advantage, particularly for patients with advanced breast cancer and limited treatment options who may experience severe side effects from other treatments. Because it is pill-based, it offers the potential to improve patients’ quality of life and perhaps delay the need for more invasive interventions.
Why is the UK approval significant?
The UK approval is a crucial step in making the treatment more widely available.It also sends a strong signal to the broader European medical community.
What is the status of Capivasertib in Italy?
while AIFA has authorized Capivasertib, it is not yet covered by the National Health Service in Italy. Procedures are underway to ensure Italian patients can access the therapy.
Experts describe Capivasertib as a “turning point.” Why?
Researchers at the Institute of cancer Research in London have hailed Capivasertib as a potential “turning point” in the treatment of breast cancer, highlighting its potential to offer an alternative approach to managing the disease.
What Are the Key Differences Between Capivasertib and Chemotherapy?
| Feature | Capivasertib | Chemotherapy |
|——————-|————————————————|————————————————-|
| Administration | Pill-based | Often intravenous (IV) |
| Target | specific protein involved in cancer cell growth | Targets rapidly dividing cells in the body |
| Potential Side Effects | Could include lower severity, improving quality of life | Can include hair loss, nausea, fatigue, etc |
| Patient Benefit| Delay more invasive interventions | Eliminate cancerous cells |
| Target Patients| HR-positive, HER2-negative breast cancers | Wide range based on diagnosis |